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Abstract
The TNM pN stage based on the number of metastatic lymph nodes is an independent prognostic factor in gastric cancer. 
Many studies have highlighted the phenomenon of stage migration and problems in comparing groups of patients with different 
numbers of total lymph nodes harvested within TNM staging. The current version of UICC/AJCC and JGCA TNM classifications 
postulates a minimal number of 16 lymph nodes as the base for N stage determination. Alternative systems such as lymph node 
ratio (LNR), positive to negative lymph node ratio (PNLNR), and LOGODDS (or LODDS), were implemented to increase the quality 
of LN assessment. These methods have reached the background in the literature, but to date no standard approach according to 
the cut-offs for the stages has been implemented. LOGODDS is the method that most reflects the number of harvested lymph 
nodes. The rationale for alternative staging methods, their correlations, and limitations are presented. 
Introduction
The need for the appropriate classification of the 
advancement of any cancer is clear. The postoperative 
pathologic staging of cancer should provide the clinician 
with information on which to base a prognosis and in-
dications for further adjuvant treatment.
In order to obtain precise data and thereby a reliable 
background for a treatment plan, the staging systems 
have evolved. This situation is observed in gastric cancer 
staging. The most variable factor in gastric cancer stag-
ing is the status of lymph nodes (LN). The topographic 
classification was used in the 4th edition of the UICC/
AJCC TNM classification and in the former Japanese 
JGCA staging system. From the 5th UICC/AJCC , through 
the 6th and current 7th edition, the number of metastat-
ic LN is the base for staging [1]. The same method is 
adopted for the JGCA classification published in English 
in 2011 [2]. This is important for the comparison of Jap-
anese and non-Japanese trial results and the common 
language of scientific discussion. The evolution of stag-
ing system indicates that there is no “ideal staging” for 
gastric cancer and many other cancers. Every update is 
criticised in a number of papers analysing some of the 
details [3]. On the other hand, UICC/AJCC and JGCA clas-
sifications require standard surgical treatment with the 
minimal number of LN retrieved. Compliance with this 
rule in many investigated groups of patients is poor [4]. 
Therefore, studies on more accurate LN staging methods 
deal both with the group of adequate and inadequate 
number of LN assessed. 
The aim of this analysis is to compare different 
methods of LN staging adopted to assess patients with 
limited numbers of LN retrieved. 
The number of lymph nodes assessed
Radical gastrectomy with D2 LN dissection is the 
standard in Japanese , NCCN (USA), and ESMO (Europe) 
guidelines and in the majority of national guidelines 
worldwide for the treatment of advanced gastric can-
cer [5]. The above-mentioned common guideline is the 
result of debate and randomised clinical trials, which 
showed no benefit in survival for extended lymph-
adenectomy (D3) when compared to D2, and the in-
crease of survival with D2 compared to D1 [6]. Of im-
portance are the acceptable mortality and morbidity 
rates of D2 lymphadenectomy in experienced centres 
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[6]. But the problem is the compliance to guidelines 
and the groups of patients treated before the guide-
lines. In the well-known INT0116 trial performed in the 
USA, even if D2 lymphadenectomy was the standard 
for this trial, the rate of D2 was about 10% [7]. Another 
study from the USA reported that at least 15 LN were 
assessed in 38% of teaching hospitals and in 31% of 
community hospitals [4]. Better adherence to guide-
lines was reported from the UK, where 74% of radical 
gastrectomies fulfilled the standard of 15 LN [8]. Dutch 
guidelines set the number at 11 LN, as a minimal stan-
dard. In the first period of implementation of this stan-
dard 49% met the criteria, but in the second period it 
was 59% [9]. The definition of D2 lymphadenectomy 
itself does not specify the number of LN harvested, but 
according to the definition of JGCA, D2 includes 13 LN 
stations (by total gastrectomy) or 11 LN stations (by 
subtotal, distal gastrectomy). Presumably, the number 
of LN should exceed the number of stations. Therefore 
the patients who had less than 13–16 nodes dissect-
ed are D1/D1+ rather than D2. On the other hand, the 
number of LN dissected within specimens is not equal 
to the number of LN examined by the pathologist. The 
quality of pathologic examination is another limitation 
of the final LN stage assessment, and it may be poor 
[10]. Both UICC/AJCC and JGCA classifications have 
“soft” requirements according to the number of LN har-
vested. TNM 7th edition: “Histological examination of 
a regional lymphadenectomy specimen will ordinarily 
include 16 or more lymph nodes.” [1].
JGCA 2012 edition: “Although it is not a prerequi-
site, the examination of 16 or more lymph nodes is rec-
ommended for N status determination.” [2].
Another phenomenon is that in patients with a high-
er number of metastatic LN usually more LN are dissect-
ed by the surgeon and/or examined by the pathologist 
[11]. A paper from China, published in 2012 [12], anal-
ysed 435 node-negative patients after D2 lymphadenec-
tomy. In this group the mean number of LN in the speci-
men was 13.5 ±4.5 and the range 1–53. In 105 patients 
1–6 LN were examined, and 16 or more LN were exam-
ined in 148 patients. The number of LN in the specimen 
may be diminished by preoperative chemotherapy or 
radiotherapy, or by previous surgery. Lower LN numbers 
are also observed in the elderly. In the above-mentioned 
study all patients with preoperative chemo- or radio-
therapy were excluded from the analysis. One should 
remember that LN may have a small (3–4 mm) diameter, 
so proper identification of LN in fatty tissue is difficult. 
Impact of numbers on survival
The pN stage is an independent prognostic factor 
in gastric cancer [13]. However, many studies indicate 
the phenomenon of stage migration [14]. The clue is 
that the small number of LN harvested is correlated 
with the lower number of metastatic LN. Therefore, pa-
tients are classified in lower than proper pN-stage. Any 
patient with total of 6 LN harvested cannot achieve 
TNM N3 stage. But some of them have another met-
astatic LN, which was not dissected or examined by 
the pathologist. In a group of proper (we do not know 
the exact number) LN examined some of the patients 
will move upwards in the stages ladder and the sur-
vival in lower stages will be better because of exclu-
sion of underestimated pN stages. The more extended 
lymphadenectomy can move some patients to more 
advanced pN stages, but cannot move them to less 
advanced one. However, when we move a patient with 
lower than average for the stage “x” survival to the 
stage “x + 1”, and the survival of this particular pa-
tient is higher than the average survival for the stage 
“x + 1”, this patient can improve the survival in both 
stages. This is the so-called Will Rogers phenomenon 
[15]. Such a situation was observed with the change 
of 6th UICC/AJCC edition to 7th edition (for example 
patients with three positive LN were moved from N1 
to N2). The increase of the number of LN assessed 
makes stage migration, or enables proper classifica-
tion with UICC/AJCC and JGCA system. This may be 
the reason why some authors reported better survival 
in subgroups of equally staged patients stratified by 
the total number of LN assessed or higher number of 
negative LN [16]. Also, the LN assessed as “negative” 
contain some cancer cells. By removal of negative, by 
the standard meaning, LN the radicality is changed 
from R1 to R0. 
Lymph nodes ratio
Quite a simple idea is to improve the staging system 
of LN by the implementation of the ratio of positive 
LN to total number of LN harvested. According to many 
authors this can decrease stage migration [17, 18]. In 
this type of staging we operate with a kind of “proba-
bility” of LN metastasis. Two positive LN over four har-
vested is equal to 4/8, 5/10, etc. In the same lymph 
node ratio (LNR) there are patients assessed otherwise 
as pN1, pN2, pN3a, and pN3b. Nevertheless, the results 
of some studies are in favour of the LNR system [18]. 
However, there is no system. Almost every paper uses 
its own classification according to the ranges of LNR in 
subgroups (Table I) [19–22]. 
Some studies are performed mostly on groups of 
patients with low total LN count, some use groups with 
a mean number of LN harvested over 20 [20]. For the 
implementation of the idea of LNR into practice there is 
a need for common intervals (subgroups) and probably 
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the assessment of the impact of the total number of LN 
on survival within subgroups.
Positive to negative lymph nodes  
and the LOGODDS
There are also studies using another ratio, positive 
LN over negative LN (PNLNR). This is a mathematical 
transformation of the LNR. 
For every patient of negative LN > 0, a, a1, a2, – 
positive LN count, b, b1, b2 – negative LN count: 
LNR = a/(a + b). When 2 patients have the same LNR: 
a1/(a1 + b1) = a2/(a2 + b2) ↔ a1(a2 + b2) = a2(a1 + b1) 
↔ a1a2 + a1b2 = a2a1 + a2b1 ↔ a1b2 = a2b1 ↔ a1/
b1 = a2/b2.
Theses 2 patients have the same ratio of positive 
to negative LN.
Therefore, the stratification by LNR will give the 
same results as stratification by PNLNR.
LOGODDS is, by the definition of the authors [23], 
the natural logarithm from the ratio of positive LN + 
0.5/negative LN + 0.5. 
The original formula is log
(pnod + 0.5)
(tnod – pnod + 0.5) ; however, 
“tnod – pnod” is the count of negative nodes and we 
will use the latter.* 
The authors of the formula did not use just the 
logPNLNR, as they commented, “to avoid singulari-
ty”. This is to avoid dividing by 0, when all LN are 
positive, and to avoid the result –∞ (minus infini-
ty) when the count of positive LN is 0. But they did 
* Note – with regard to using logarithms, reference is made to the 
“natural logarithm”, that is, a logarithm to base e, which is usually 
denoted by ln(x); however, the formula log
(pnod + 0.5)
(tnod – pnod + 0.5)  uses 
the notation “log”, which is more often used for a logarithm to 
base 10; this does not materially affect how the formula works 
for means of comparison (although of course the answers for in-
dividual sets will differ) and using “log” does have the advantage 
of avoiding the confusion between the natural logarithm ln and 
the abbreviation LN for lymph node.
not comment on other consequences of adding 0.5. 
Without this the ratio 1/5 is equal to 2/10, which is 
in turn equal to 3/15, etc. With +0.5 the ratio is 1/5 
> 2/10 > 3/15, etc. Consequently, LOGODDS are 1/5 
> LOGODDS 2/10 > LOGODDS 3/15, etc. At the same 
time for the ratios 1/5, 4/16, and 7/27, LOGGODS are 
equal. Therefore, we have the function that reflects 
the number of dissected LN. It would better reflect the 
number of LN dissected when the added factor was 
0.75 or 1.15, for example. On the other hand, there 
is no need to use logarithms for this purpose. It has 
no additional value for staging. Instead of LOGODDS 
one may use the ratio positive LN + 0.5/negative LN 
+ 0.5 in staging, and the results are the same. It is 
important to note that the LNR (probability), PNLNR 
(odds ratio), and log(PNLNR) all provide the same in-
formation.
What is the difference?
There is no difference in staging between LNR and 
PNLNR when the cutoffs correspond to one another. As 
an example, LNR cut-off 0.25 corresponds the value of 
0.66 for PNLNR. 
There is no correspondence of LNR (or PLNR) to 
LOGODDS because one LNR (PNLNR) has more than 
one value of LOGODDS. The reasons were clarified in 
the section above. The difference between LOGODDS 
results for a given value of LNR (PLNR) depends on the 
difference between the number of LN examined [24].
The pN and LOGODDS staging relation is different 
when an increased number of LN is examined (Figure 1). 
The cut-offs used by Sun et al. [23] and those published 
by Qiu et al. [25] differ mainly in less advanced stages. 
Stage 1–3 by Sun et al. is equal to Stage 1 by Qiu et al. 
Stage 4 of the first classification is equal to Stage 2 of 
the second. For 6 LN harvested there is no Stage 3 by 
Qiu. The classification proposed by Qiu et al. in stage 1 
has in case of 16 LN harvested 0-5 metastatic LN and 
Table I. The cutoffs of the studies using LNR 
Author Patients (mean LN number) LNR cut-offs
Pedrazzani et al. 2010 [20] 526 (5.6) 0, 0.1–0.25, > 0.25
Liu et al. 2007 [17] 224 (28.1) 0, 0.1–0.4, 0.41–0.8, > 0.8
Wang et al. 2012 [18]1 18 403 (10–11) 0–0.067, 0.068–0.3, 0.31–0.7, > 0.7
Lee et al. 2012 [21] 370 (37) 0.0–0.01, 0.02–0.05, 0.06–0.1, 0.11–0.20, 0.20–0.30, > 0.30
Espin et al. 2012 [11] 96 (22–31) < 0.2, ≥ 0.2
Huang et al. 2010 [22] 634 (23.1) 0.1–0.2, 0.21–0.5, > 0.5
Kulig et al. 2009 [19] 735 (8) < 0.4, ≥ 0.4
1Wang et al. use pNR0 only for patients with more than 15 LN harvested.
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0–8 metastatic LN by 24 LN harvested. Therefore, we 
think it is more suitable for limited lymphadenectomy. 
Metastatic lymph nodes are not 
independent 
Lymph node status is an independent prognostic 
factor in gastric cancer almost regardless of the staging 
method. But there are other prognostic factors such as 
T stage, M stage, vascular involvement, and histologic 
type of the tumour [26, 27]. N status is also related 
to other factors because different incidences of LN 
metastases are observed in different T stages [27]. On 
the other hand, metastasis to the specific LN stations 
may be correlated with the poor prognosis [28]. There-
fore, even with the most accurate classification of the 
N stage there is a possibility of subgroups with differ-
ent survival within one N stage. Some other methods 
are implemented to predict individual survival, such as 
computer programs [29] or simpler nomograms [30] us-
ing more extensive data. 
Conclusions
As the nature of gastric cancer is complex, it is prob-
ably not possible to predict the course of the disease 
with a single measure, which is N status. The additional 
confounding factor is the extent of lymphadenectomy 
and subsequent pathologic assessment of lymph nodes. 
The small number of examined lymph nodes produc-
es low-quality data. Alternative systems such as LNR, 
PNLNR, and LOGODDS (or ODDS + 0.5) were imple-
mented to increase the quality of LN assessment. The 
main obstacle in the assessment of alternative staging 
methods is the lack of standard cutoffs for the stages. 
Another obstacle is the lack of common standards of 
lymphadenectomy. It is obvious that the level of dissec-
tion is different with 5–10 nodes harvested than with 
25 nodes, even if it is called in both cases D2. The solu-
tion of this problem may be the common standard of 
staging for less than 16 LN, and another for 16 or more 
LN harvested. Some of the proposed methods provide 
the same information, and it is not surprising that the 
results are fully comparable. With LOGODDS the differ-
ence is made by the addition of a value of 0.5 to both 
to numerator and denominator, which itself is quite ran-
domly selected among non integers. There is no proof 
that 0.5 is optimal for such an assessment. 
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